Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: A meta-analysis

Digestive and Liver Disease

Volumn 48, Issue 4, 2016, Pages 353-359

  Yu, Ting ^a   Tang, Yurong ^a   Jiang, Liuqin ^a   Zheng, Yongping ^a   Xiong, Wenjie ^a   Lin, Lin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bacterial infections; Liver cirrhosis; Meta analysis; Proton pump inhibitors

Indexed keywords

PROTON PUMP INHIBITOR;

BACTERIAL PERITONITIS; COHORT ANALYSIS; HOSPITALIZATION; HUMAN; INCIDENCE; LIVER CIRRHOSIS; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVIEW; BACTERIAL INFECTION; CASE CONTROL STUDY; COMPLICATION; ODDS RATIO; PERITONITIS; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

BACTERIAL INFECTIONS; CASE-CONTROL STUDIES; COHORT STUDIES; HOSPITALIZATION; HUMANS; INCIDENCE; LIVER CIRRHOSIS; ODDS RATIO; PERITONITIS; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84960937001     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.12.009     Document Type: Review

References (44)

1. Wiest R., Krag A., Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012, 61:297-310.
2. Scarpellini E., Valenza V., Gabrielli M., et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed?. American Journal of Gastroenterology 2010, 105:323-327.
3. Guarner C., Runyon B.A., Young S., et al. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. Journal of Hepatology 1997, 26:1372-1378.
4. Chang C.S., Chen G.H., Lien H.C., et al. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1998, 28:1187-1190.
5. Wiest R., Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005, 41:422-433.
6. Rabinovitz M., Gavaler J.S., Kumar S., et al. Role of serum complement, immunoglobulins, and cell-mediated immune system in the pathogenesis of spontaneous bacterial peritonitis (SBP). Digestive Diseases and Sciences 1989, 34:1547-1552.
7. Targownik L.E., Metge C., Roos L., et al. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. American Journal of Gastroenterology 2007, 102:942-950.
8. Garcia-Tsao G., Sanyal A.J., Grace N.D., et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007, 46:922-938.
9. Norberto C., Felix I., Jorge G.L., et al. Use and overuse of proton pump inhibitors in cirrhotic patients. Medical Science Monitor 2008, 9:468-472.
10. Jacobs C., Coss Adame E., Attaluri A., et al. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Alimentary Pharmacology and Therapeutics 2013, 37:1103-1111.
11. Bajaj J.S., Zadvornova Y., Heuman D.M., et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. American Journal of Gastroenterology 2009, 104:1130-1134.
12. Goel G.A., Deshpande A., Lopez R., et al. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clinical Gastroenterology and Hepatology 2012, 10:422-427.
13. Deshpande A., Pasupuleti V., Thota P., et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Journal of Gastroenterology and Hepatology 2013, 28:235-242.
14. Trikudanathan G., Israel J., Cappa J., et al. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - a systematic review and meta-analysis. International Journal of Clinical Practice 2011, 65:674-678.
15. Min Y.W., Lim K.S., Min B.H., et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Alimentary Pharmacology and Therapeutics 2014, 40:695-704.
16. Mandorfer M., Bota S., Schwabl P., et al. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. PLOS ONE 2014, 9:e110503.
17. Kwon J.H., Koh S.J., Kim W., et al. Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. Journal of Gastroenterology and Hepatology 2014, 29:775-781.
18. O'Leary J.G., Reddy K.R., Wong F., et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clinical Gastroenterology and Hepatology 2014, 4. 753-9.e1-2.
19. Terg R., Casciato P., Garbe C., et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. Journal of Hepatology 2015, 5:1056-1060.
20. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. British Medical Journal 2009, 339:b2535.
21. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology 2010, 25:603-605.
22. Davies H.T., Crombie I.K., Tavakoli M. When can odds ratios mislead?. British Medical Journal 1998, 316:989-991.
23. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002, 21:1539-1558.
24. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. British Medical Journal 2003, 327:557-560.
25. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997, 315:629-634.
26. Higgins J.P., Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated march] the cochrane collaboration 2011, Available from. http://www.cochrane-handbook.org/.
27. Campbell M.S., Obstein K., Reddy K.R., et al. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Digestive Diseases and Sciences 2008, 53:394-398.
28. Northup P.G., Argo C.L., Berg C.L. Chronic proton pump inhibitor use is strongly associated with hepatorenal syndrome and spontaneous bacterial peritonitis in cirrhosis patients. Hepatology 2008, 48:325a.
29. Bulsiewicz W.J., Scherer J.R., Feinglass J.M., et al. 63 proton pump inhibitor (PPI) use is independently associated with spontaneous bacterial peritonitis (SBP) in cirrhotics with ascites. Gastroenterology 2009, 136:A11.
30. Choi E.J., Lee H.J., Kim K.O., et al. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Scandinavian Journal of Gastroenterology 2011, 46:616-620.
31. van Vlerken L.G., Huisman E.J., van Hoek B., et al. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. European Journal of Clinical Investigation 2012, 42:760-767.
32. Aditi A., Crippin J.S., Abhishek A. Role of proton pump inhibitors in the development of spontaneous bacterial peritonitis amongst cirrhotics; a retrospective cohort study. Gastroenterology 2012, 142:S-946.
33. de Vos M., De Vroey B., Garcia B.G., et al. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Liver International 2013, 33:1316-1323.
34. Miura K., Tanaka A., Yamamoto T., et al. Proton pump inhibitor use is associated with spontaneous bacterial peritonitis in patients with liver cirrhosis. Internal Medicine 2014, 53:1037-1042.
35. Ratelle M., Perreault S., Villeneuve J.P., et al. Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Canadian Journal of Gastroenterology & Hepatology 2014, 28:330-334.
36. Mann C.J. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emergency Medicine 2003, J20:54-60.
37. Law D., Pimentel M. Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS. Digestive Diseases and Sciences 2010, 55:2302-2308.
38. Choung R.S., Ruff K.C., Malhotra A., et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Alimentary Pharmacology and Therapeutics 2011, 33:1059-1067.
39. Lombardo L., Foti M., Ruggia O., et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clinical Gastroenterology and Hepatology 2010, 8:504-508.
40. Thorens J., Froehlich F., Schwizer W., et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996, 39:54-59.
41. Naunton M., Peterson G.M., Bleasel M.D. Overuse of proton pump inhibitors. Journal of Clinical Pharmacy and Therapeutics 2000, 25:333-340.
42. Dultz G., Piiper A., Zeuzem S., et al. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Alimentary Pharmacology and Therapeutics 2015, 41:459-466.
43. Lodato F., Azzaroli F., Di Girolamo M., et al. Proton pump inhibitors in cirrhosis: tradition or evidence based practice?. World Journal of Gastroenterology 2008, 14:2980-2985.
44. Chavez-Tapia N.C., Tellez-Avila F.I., Garcia-Leiva J., et al. Use and overuse of proton pump inhibitors in cirrhotic patients. Medical Science Monitor 2008, 14:CR468-CR472.